The CEACAM5 drugs market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer and the increasing number of CEACAM5 that ...
SAN FRANCISCO and SUZHOU, China, April 29, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and ...
First-in-human trial of SYS6010 combined with SYH2051 in patients with advanced gastrointestinal tumors. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...
TAMPA and LONDON, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company pioneering next-generation antibody drug conjugates (ADCs) powered by ...
Oncotarget recently published "Heterogeneity of CEACAM5 in breast cancer" which reported that Here, we examined a repository of 110 cryopreserved primary breast carcinomas by immunohistochemistry to ...
Two early-phase clinical trials presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting by researchers from The University of Texas MD Anderson Cancer Center demonstrate ...
The carcinoembryonic antigen (CEA) family represents one of the most divergent group of glycoproteins in mammals with respect to sequence and structure (Zimmermann, 1998; Hammarström, 1999). The human ...
Akari Therapeutics has filed a new US provisional patent covering AKTX-102, its second antibody drug conjugate targeting CEACAM5, a solid tumour marker expressed across several high‑unmet‑need cancers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results